GenScript Biotech

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Built upon leading gene synthesis technology, GenScript consists of four major groups:
GenScript was founded in New Jersey, United States in 2002, by Dr. Fangliang (Frank) Zhang, and listed on the Hong Kong Stock Exchange in 2015. Currently, GenScript is under the leadership of rotating CEO, Dr. Zhenyu Liu., GenScript's business operations span over 100 countries and regions worldwide with legal entities located in the US, China, Hong Kong, Japan, Singapore, the Netherlands, and Ireland. GenScript provides products and services to over 100,000 customers., 
As of June 30, 2020, GenScript had more than 3,900 employees globally, over 36% of whom hold master's and/or Ph.D. degrees. In addition, GenScript owns a number of intellectual property rights and trade secrets, including over 140 patents and over 450 pending patent applications.
GenScript is driven by the corporate mission of “making people and nature healthier through biotechnology”. As of June 30, 2020, GenScript's products or services have been cited by 51,000 peer-reviewed journal articles worldwide.
In September 2020 it was reported Chairman and founder of Genscript Fangliang Zhang was arrested and put under “residential surveillance,” due to alleged breaches of China's tight rules on the exports of human genetic resources. Anti-smuggling officials also raided their offices in Nanjing and Shenjiang, with Genscript stating they would assist authorities with the investigation.
GenScript Biotech’s business segments.
GenScript Life Science Group.
GenScript Life Science Group is GenScript's original business unit. Based on its independent and leading gene synthesis technology, the GenScript Life Science business has grown to become the world's largest gene synthesis provider with a market share of approximately 30%. The Group now has nearly 2,000 employees worldwide, covering China, North America, Europe, and Asia Pacific.
For over 20 years, GenScript Life Science Group has supported global scientists achieve research results and promoted the rapid advancement of life sciences over the past 20 years. In 2011, GenScript was selected as the sole business entity to participate in the Synthetic Yeast Genome Sc2.0 Project. As of December 31, 2019, GenScript Life Science Group has delivered more than 2 million genes at a 99.95% success rate and over 98.5% on-time delivery rate, as well as 100% sequence accuracy rate. The delivered products have been cited in more than 42,200 scientific papers. Throughout the past decade, GenScript was awarded the CRO Leadership Award by Life Science Leader Magazine several times in the categories of quality, productivity, innovation, and reliability.
Supported by next-generation DNA Synthesis and HD Protein Expression technologies, GenScript's Life Science CRO platform continues to expand its business strategy in five application areas - retail reagents, industrial solutions, therapeutic materials, supportive diagnostic materials and research instruments and consumables - providing global scientists with simple, fast and precise scientific research solutions and harnessing the power of synthetic biology to speed up pharmaceutical R&D., , 
GenScript ProBio – Bio-pharmaceutical CDMO.
GenScript ProBio is the bio-pharmaceutical CDMO segment, providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes to accelerate drug development.
GenScript ProBio provides solutions for antibody drug development including antibody drug discovery (hybridoma, antibody library, fully human transgenic mice, bispecific antibodies technologies, single B cell screening technology), antibody engineering (antibody humanization, affinity maturation, Fc Engineering), and antibody characterization (analytics and bioassays). For biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development to clinical manufacturing services, providing high quality materials for IND and clinical trials to accelerate the drug development process. GenScript ProBio's total gene and cell therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing.
GenScript ProBio follows the corporate mission of “Innovation through Collaboration”, to shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs.
Legend Biotech – Cell Therapy.
A a subsidiary of GenScript Biotech Corporation, Legend Biotech (NASDAQ: LEGN) is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncological and other indications. Legend Biotech's team includes over 650 employees across the United States, China and Europe. Along with differentiated technology, development, and manufacturing strategies and expertise, Legend Biotech is engaged in the discovery, development, and manufacturing of cell therapies for patients in need.
Legend Biotech has established a strategic collaboration with Janssen Biotech to develop and commercialize the lead product candidate, LCAR-B38M/JNJ-4528, an investigational BCMA-targeted CAR-T cell therapy for patients living with relapsed or refractory multiple myeloma. This candidate is currently being studied in registrational clinical trials.
Bestzyme – Industrial Synthesis Product.
Nanjing Bestzyme Bioengineering Co., Ltd. (Bestzyme), is one of GenScript's subsidiaries integrating the development of enzyme preparations and the development, production, and sales of enzyme catalysis technology for active product ingredients (APIs). Dedicated to biosynthesis technology, Nanjing Bestzyme has established a fully integrated end-to-end system incorporating development, production and marketing - from enzyme screening, genetic engineering, protein engineering transformation, fermentation process optimization, application research to technical support and follow-up services.
Established in 2013, Nanjing Bestzyme drives innovation through "independent R&D, core technology advancement, and complete ownership of intellectual property rights." Nanjing Bestzyme has independently developed multiple industrial, food and medical enzyme products such as pullulanase, phytase and glucose oxidase, in addition to a number of product lines with industry-leading performance.
History and Achievements.
2002, GenScript was founded in New Jersey, USA.
2004, GenScript established research and production center in Nanjing, China.
2011, GenScript opened a new Nanjing research and production facility and established a subsidiary in Japan.
2013, GenScript launched Bestzyme (biotech industrial synthetic biology) product segment.
2014, GenScript launched Legend Biotech cell therapy segment.
2015, GenScript Biotech Corporation was listed in HKEK (Stock code:1548).
2017, the China Food and Drug Administration (CFDA) accepted the IND application by Legend. Collaboration on BCMA program was established between Legend and Janssen.
2018, Legend's BCMA program received IND clearance in the United States and China. GenScript's Biologics CDMO segment was established.
2019, GenScript launched its new Biologics GMP CDMO R&D center and established its European and Asia-Pacific division. Legend's BCMA program received Orphan drug designation (FDA) & PRIME designation (EMA), US phase 1b data at ASH 2019: ORR 100%.
2020, GenScript Life Science CRO achieved consecutive growth. GenScript and Duke-NUS Medical School co-developed cPass sVNT kit, first in the world SARS-CoV-2 serology test to detect neutralizing antibodies., , Legend Biotech was listed on NASDAQ (stock code: LEGN), the biggest IPO for a biotech company 2020., 